Hudson Capital Management LLC acquired a new stake in Taro Pharmaceutical Industries Ltd. (NYSE:TARO) during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 6,732 shares of the company’s stock, valued at approximately $705,000.

A number of other hedge funds have also added to or reduced their stakes in the stock. Wells Fargo & Company MN raised its stake in Taro Pharmaceutical Industries by 11.2% during the 2nd quarter. Wells Fargo & Company MN now owns 1,685 shares of the company’s stock valued at $189,000 after buying an additional 170 shares during the last quarter. Dynamic Technology Lab Private Ltd purchased a new stake in Taro Pharmaceutical Industries during the 2nd quarter valued at $234,000. Russell Investments Group Ltd. raised its stake in Taro Pharmaceutical Industries by 7.4% during the 2nd quarter. Russell Investments Group Ltd. now owns 2,257 shares of the company’s stock valued at $253,000 after buying an additional 156 shares during the last quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp raised its stake in Taro Pharmaceutical Industries by 88.9% during the 3rd quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 3,400 shares of the company’s stock valued at $383,000 after buying an additional 1,600 shares during the last quarter. Finally, Highstreet Asset Management Inc. raised its stake in Taro Pharmaceutical Industries by 66.1% during the 3rd quarter. Highstreet Asset Management Inc. now owns 3,621 shares of the company’s stock valued at $408,000 after buying an additional 1,441 shares during the last quarter. 13.41% of the stock is currently owned by institutional investors and hedge funds.

Separately, BidaskClub lowered shares of Taro Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research note on Thursday, October 12th.

Shares of Taro Pharmaceutical Industries Ltd. (NYSE TARO) traded down $0.17 on Tuesday, reaching $104.90. 93,700 shares of the company’s stock were exchanged, compared to its average volume of 87,043. The stock has a market cap of $4,210.00, a price-to-earnings ratio of 12.93 and a beta of 0.62. Taro Pharmaceutical Industries Ltd. has a 1-year low of $94.00 and a 1-year high of $128.46.

Taro Pharmaceutical Industries (NYSE:TARO) last announced its earnings results on Tuesday, November 7th. The company reported $1.30 earnings per share for the quarter. Taro Pharmaceutical Industries had a net margin of 44.07% and a return on equity of 15.66%.

ILLEGAL ACTIVITY WARNING: “Hudson Capital Management LLC Invests $705,000 in Taro Pharmaceutical Industries Ltd. (TARO) Stock” was published by Watch List News and is owned by of Watch List News. If you are viewing this piece on another website, it was copied illegally and republished in violation of United States and international trademark & copyright law. The original version of this piece can be accessed at https://www.watchlistnews.com/hudson-capital-management-llc-invests-705000-in-taro-pharmaceutical-industries-ltd-taro-stock/1820287.html.

Taro Pharmaceutical Industries Company Profile

Taro Pharmaceutical Industries Ltd. (Taro) is a science-based pharmaceutical company. The Company operates principally through three entities: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries, Taro Pharmaceuticals Inc (Taro Canada) and Taro U.SA The Company markets over 200 pharmaceutical products in over 25 countries.

Want to see what other hedge funds are holding TARO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Taro Pharmaceutical Industries Ltd. (NYSE:TARO).

Institutional Ownership by Quarter for Taro Pharmaceutical Industries (NYSE:TARO)

Receive News & Ratings for Taro Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.